Antiphospholipid antibodies and fetal loss

Michael D. Lockshin, Lisa R. Sammaritano, D. Ware Branch, Donald J. Dudley, James R. Scott, Robert M. Silver, Azzudin E. Gharavi, Ronald A. Asherson, E. Nigel Harris, Joseph A. Spinnato, Silvia Pierangeli, m. Birdsall, N. S. Pattison, Claire Infante-Rivard, Michèle David, Robert Gauthier, Georges Etienne Rivard

Resultado de la investigación: Letterrevisión exhaustiva

7 Citas (Scopus)


To the Editor: Infante-Rivard and colleagues (Oct. lO issue)1 make an important point that enzyme-linked immunosorbent assays (ELISAs) that can detect low titers of lupus anticoagulant and antiphospholipid antibodies do not distinguish between normal pregnant women and women who have recently had a first miscarriage. However, in stating that “previous investigators have postulated that lupus anticoagulants or anticardiolipin antibodies become risk factors only after a number of fetal losses,” the authors misread earlier data and attempt to answer a question that their study cannot ask. There is consensus that antiphospholipid antibody, used as a marker, is rarely present in normal.

Idioma originalEnglish (US)
Páginas (desde-hasta)951-954
Número de páginas4
PublicaciónNew England Journal of Medicine
EstadoPublished - abr 2 1992
Publicado de forma externa

ASJC Scopus subject areas

  • Medicine(all)


Profundice en los temas de investigación de 'Antiphospholipid antibodies and fetal loss'. En conjunto forman una huella única.

Citar esto